Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure

Diabetes, Obesity and Metabolism

Volumn 5, Issue 6, 2003, Pages 371-378

  Altuntas, Yuksel ^a,b   Ozen, B ^a   Ozturk, B ^a   Sengul, A ^a   Ucak, S ^a   Ersoy, O ^a   Karul, S ^a  

^a Sisli Etfal Education/Res Hospital   (Turkey)

^b Haznedar Mah   (Turkey)

Author keywords

Lispro insulin; Metformin; OAD failure; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMILIN N; HUMILIN R; INSULIN; INSULIN LISPRO; ISOPHANE INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DISEASE DURATION; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0345328777     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2003.00283.x     Document Type: Article

References (21)

1. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997; 20: 1822-1826.
2. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association Diagnostic Criteria, the DECODE Study Group. European Diabetes Epidemiology Group, Diabetes Epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999; 354: 617-621.
3. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
4. de Veciana M, Major CA, Morgan MA et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995; 333: 1237-1241.
5. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28),Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-404.
6. Jovanovic L. Rationale for prevention and treatment of postprandial glucose-mediated toxicity. Endocrinologist 1999; 9: 87-92.
7. 1c influenced more strongly by preprandial or postprandial glycemia in type 1 Diabetes? Diabetes Care 2002; 25: 1100-1101.
8. 1c interrelationships in type 2 diabetes. Diabetes Care 2001; 24: 2023-2029.
9. 1c. Diabetes Care 2000; 23: 1236-1241.
10. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999; 42: 1151-1167.
11. Anderson JH, Brunelle RL, Keohane P et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157: 1249-1255.
12. Ross SA, Zinman B, Campos RV, Strack T. Canadian Lispro Study Group. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med 2001; 24: 292-298.
13. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification on Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
14. Richmond W. Preparation and properties of a cholesterol oxidase from Nocerdia sp. & its application to the enzymatic assay of total cholesterol in serum. Clin Chem 1973; 19: 1350-1356.
15. Sullivan DR, Kruijswijk Z, West CE, Kohlmeier M, Katan MB. Determination of serum triglyceride by an accurate enzymatic method not affected by free glycerol. Clin Chem 1985; 31: 1227-1228.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
17. Bastyr EJ, Johnson ME, Trautmann ME, Anderson JH, Vignati L and the IOCE Study Group. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 1999; 22: 1703-1714.
18. Bell DS. Importance of postprandial glucose control. South Med J 2001; 94: 804-809.
19. Tong PC, Chow CC, Jorgensen LN, Cockram CS. The contribution of metformin to glycaemic control in patients with type 2 diabetes mellitus receiving combination therapy with insulin. Diabetes Res Clin Pract 2002; 57: 93-98.
20. Holleman F, Hoekstra J. Insulin lispro. N Engl J Med 1997; 17: 176-182.
21. Heller SR, Amiel SA, Evans ML, Kong MF, Macdonald IA, Peacey SR. Does insulin lispro preserve the physiological defences to hypoglycaemia during intensive insulin therapy with a conventional basal bolus regimen? Diabetes Obes Metab 2002; 4: 106-112.